IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.298
AS - Asia 3.258
EU - Europa 1.179
SA - Sud America 755
AF - Africa 178
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 10.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.183
SG - Singapore 2.003
BR - Brasile 607
CN - Cina 496
VN - Vietnam 307
FI - Finlandia 230
IT - Italia 218
IE - Irlanda 163
DE - Germania 128
NG - Nigeria 117
HK - Hong Kong 100
FR - Francia 96
SE - Svezia 75
CA - Canada 74
GB - Regno Unito 73
IN - India 60
AR - Argentina 54
NL - Olanda 52
TR - Turchia 45
BD - Bangladesh 40
ID - Indonesia 32
IQ - Iraq 30
EC - Ecuador 26
IL - Israele 25
PL - Polonia 25
MX - Messico 21
RU - Federazione Russa 18
JP - Giappone 17
BE - Belgio 16
ZA - Sudafrica 16
CL - Cile 15
CO - Colombia 15
VE - Venezuela 14
PK - Pakistan 13
UA - Ucraina 13
ES - Italia 12
SA - Arabia Saudita 12
PY - Paraguay 11
MA - Marocco 10
AT - Austria 8
PH - Filippine 8
DZ - Algeria 7
EG - Egitto 7
MY - Malesia 7
TN - Tunisia 7
UY - Uruguay 7
UZ - Uzbekistan 7
LT - Lituania 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
KZ - Kazakistan 5
TW - Taiwan 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
EU - Europa 4
GE - Georgia 4
IR - Iran 4
JM - Giamaica 4
KE - Kenya 4
LB - Libano 4
PE - Perù 4
AU - Australia 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EE - Estonia 3
HU - Ungheria 3
LV - Lettonia 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
ET - Etiopia 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
KG - Kirghizistan 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
MK - Macedonia 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
Totale 10.665
Salva come PNG Salva come JPEG
Città #
Singapore 894
Wilmington 706
Chandler 508
Ashburn 432
Dallas 361
The Dalles 315
San Mateo 299
San Jose 274
Helsinki 229
Shanghai 216
New York 209
Ann Arbor 189
Dublin 163
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Beijing 111
Ho Chi Minh City 105
Hong Kong 97
Milan 92
Woodbridge 81
Boardman 80
Paris 72
Los Angeles 65
Phoenix 64
Hanoi 63
São Paulo 62
Fairfield 60
Santa Clara 45
Toronto 45
Amsterdam 43
London 38
Seattle 32
Kocaeli 29
Buffalo 28
Orem 23
Warsaw 22
San Diego 21
Naples 20
Rio de Janeiro 18
Da Nang 16
Belo Horizonte 15
Brussels 15
Pune 15
Chennai 13
Council Bluffs 13
Chicago 12
Norwalk 12
Baghdad 11
Boston 11
Guayaquil 11
Haiphong 11
Mexico City 11
Montreal 11
Porto Alegre 11
Tokyo 11
Erbil 10
Hillsboro 10
Curitiba 9
Manchester 9
San Francisco 9
Stockholm 9
Abbiategrasso 8
Brasília 8
Brooklyn 8
Columbus 8
Denver 8
Dhaka 8
Monmouth Junction 8
Munich 8
Santiago 8
Atlanta 7
Charlotte 7
Falkenstein 7
Fortaleza 7
Johannesburg 7
Reston 7
Tashkent 7
Thái Nguyên 7
Biên Hòa 6
Buenos Aires 6
Genoa 6
Goiânia 6
Guarulhos 6
Miami 6
Montevideo 6
Moscow 6
Nanjing 6
New Delhi 6
Quito 6
Asunción 5
City of London 5
Des Moines 5
Jacksonville 5
Karachi 5
Manaus 5
Pretoria 5
Redmond 5
Riyadh 5
Totale 7.095
Salva come PNG Salva come JPEG
Nome #
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 133
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 127
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 127
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 123
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 123
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 122
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 119
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy 110
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 109
COVID-19 and liver cancer clinical trials: not everything is lost 108
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 106
Treatment of malignant pleural mesothelioma: current status and future directions 106
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 104
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 103
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 103
Advances in the biology of malignant pleural mesothelioma 102
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 101
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 100
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 98
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 95
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 94
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 90
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 90
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 89
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 88
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 88
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 87
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 86
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 86
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 86
Reproducibility of the WHO classification of thymomas: practical implications 86
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 85
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 84
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 84
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 83
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 83
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 83
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 83
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 83
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 82
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 82
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 81
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 80
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 80
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 80
Neutrophils in Gliomas 79
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 79
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 79
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 78
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 77
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 77
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 77
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 77
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 76
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 76
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 76
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 76
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 75
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 74
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 73
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 73
Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series 72
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 72
Imaging biomarkers in primary brain tumours 72
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors 71
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 71
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events 70
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 70
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 70
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 70
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 69
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 69
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 68
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 68
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 67
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 67
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 67
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions 66
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 65
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 65
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes 65
Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study 64
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 64
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 64
Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study 64
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 63
Future developments in the management of malignant pleural mesothelioma 63
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 63
First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer 63
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 62
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey 62
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 62
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 61
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 61
Intensified chemotherapy with stem-cell rescue in germ-cell tumors 61
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study 61
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 60
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 60
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 60
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 60
Totale 8.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021170 0 0 0 0 0 0 0 0 0 0 0 170
2021/2022689 32 5 13 139 4 6 28 102 55 71 199 35
2022/20231.536 285 66 162 148 120 99 3 119 261 153 107 13
2023/20241.113 58 108 171 39 45 251 88 47 11 32 109 154
2024/20251.553 33 17 10 27 33 162 64 166 270 359 197 215
2025/20264.484 609 416 370 484 134 264 1.095 241 236 299 175 161
Totale 10.845